- Policy
- MOHW to provide premium pricing support for innovative drugs
- by Lee, Jeong-Hwan Sep 7, 2022 05:52am
- The Korean government has emphasized the need to enact subordinate statutes to give preferential treatment to new drugs manufactured by Korea Innovative Pharmaceutical Companies and promises to prepare policy support. This announcement reflects the authorities’ determination to find a way to provide preferential treatment for drug prices
- Policy
- What's patient-centered safety in the biopharmaceutical era?
- by Lee, Hye-Kyung Sep 7, 2022 05:52am
- Along with the application of the world's first CAR-T cell therapy Kymriah and Zolgensma, an alternative treatment for spinal proximal phagocytosis (SMA), the biopharmaceutical era has opened in Korea. Controversy over safety and accessibility has not yet been resolved in the process of innovative biopharmaceuticals being developed and used to t
- Policy
- Antiemetic Emend's generic benefit after 15 yrs since origin
- by Lee, Tak-Sun Sep 7, 2022 05:51am
- As the generic of Emend will be applied starting this month, the burden of drug prices for patients is expected to decrease. It is the first time in 15 years that generic for Emend capsule has been reimbursed since the original was listed. According to industries on the 5th, Acepharma's Atant 80mg and Atant 125mg have been registered as be
- Policy
- Enactment of preferential pricing sublaws slow
- by Lee, Jeong-Hwan Sep 6, 2022 05:51am
- The enactment of subordinate statutes for the so-called ‘preferential drug pricing for Korean Innovative Pharmaceutical Companies’ clause of the ‘Special Act On Fostering and Support of Pharmaceutical Industry’ is hardly picking up speed. Although the research service ordered by the Ministry of Health and Welfare and the Korea Health
- Policy
- The goal shorten the development of mRNA vaccine to 100 days
- by Lee, Hye-Kyung Sep 6, 2022 05:51am
- SK Bioscience, which developed Korea's No. 1 COVID-19 vaccine, aims to shorten the development period of the mRNA vaccine to 100 days and create innovative technology that can be supplied to the world within six months. 1 Choi Chang-won, vice chairman of SK Discovery's CEO, gave a keynote speech at the "2022 Global Bio Conference" held at Gra
- Policy
- Checking the effectiveness of SKYCovione,
- by Kim, Jung-Ju Sep 6, 2022 05:51am
- SKYCovione, South Korea's No. 1 COVID-19 vaccine developed by SK Bioscience, has been confirmed to have an additional vaccination effect in the cross-neutralization of the omicron mutation virus (BA.1, BA.5). Korea National Institute of Health (Director Kwon Joon-wook) announced on the 2nd that it has confirmed cross-neutralizing anti-bibo
- Policy
- Including SKYCovione, 6 types of COVID-19 vaccines
- by Lee, Jeong-Hwan Sep 6, 2022 05:51am
- With the seventh outbreak of COVID-19 expected this winter, the type of COVID-19 vaccine and the age of vaccination are expected to expand ahead of the winter vaccination. Following the previously licensed Pfizer, Moderna, and Janssen vaccines, domestic SK Bioscience vaccines have been approved, and additional vaccines for omicron mutation
- Policy
- Drugs granted conditional approv to report clinical progress
- by Lee, Hye-Kyung Sep 5, 2022 05:55am
- Treatments for life-threatening serious and rare diseases are being granted conditional approval from July 21st this year. However, to inform the public of the conditions, items for which data on confirmatory clinical trials were not submitted should be specified in the label’s indication, and the clinical trial status of the subject drugs
- Policy
- MFDS has launched permission review for Pfizer Comirnaty 2
- by Kim, Jung-Ju Sep 5, 2022 05:55am
- Pfizer's COVID-19 2-valent vaccine Comirnaty2 0.1mg/mL permission review has begun. The Ministry of Food and Drug Safety (Director Oh Yoo-kyung) announced that Pfizer Korea has applied for permission today (29th) to import 0.1mg/mL of Comirnati 2, an mRNA-type bivalent vaccine that expresses the initial COVID-19 virus and mutant virus (Omi
- Policy
- Will Migraine drug Ajovy be reimbursed following Emgality?
- by Lee, Tak-Sun Sep 2, 2022 06:03am
- With the new migraine drug Emgality (galcanezumab, Lilly) being applied reimbursement in Korea starting this month, a green light has been given to Teva-Handok’s new migraine drug as well. The new drug has passed the reimbursement adequacy assessment of the Health Insurance Review and Assessment Service, after which the company will be enter
